Clinical trial · Interventional
Idarubicin Plus Cytarabine (IA) vs IA Plus Cladribine (IAC) as Induction Regimen to Treat Initially Diagnosed Acute Myeloid Leukemia (AML)
IAC Regimen Versus IA Regimen as Induction Treatment for Initially Diagnosed AML Patients: a Randomized Controlled Phase III Clinical Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial is to compare the clinical efficacy and safety of IAC regimen and IA regimen as induction chemotherapy for initial diagnosed acute myeloid leukemia (AML) patients. The main question it aims to answer is: •Does IAC regimen higher the complete remission rate in initial diagnosed AML patients? Researchers will compare IAC regimen to IA regimen to see if IAC works to treat AML. Participants will: * Receive IAC or IA as induction regimen * Receive a second cycle of re-induction if partial remission * Visit the clinic once every 3 to 6 months for assessment
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| IAC regimen | Drug | — | UNRESOLVED |
| IA regimen | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- IAC regimen
- description
- Receive IAC induction therapy
- interventionNames
- Drug: IAC regimen
- type
- ACTIVE_COMPARATOR
- label
- IA regimen
- description
- Receive an IA induction therapy
- interventionNames
- Drug: IA regimen
Primary outcomes (1)
- measure
- Complete Remission Rate
- timeFrame
- 1-2 months
- description
- complete remission (CR) rate after the induction courses
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * Initially diagnosed as AML (except APL) * Aged between 18 and 60 year old * Eastern Cooperative Oncology Group (ECOG) score no more than 3 * Informed consent file (ICF) signed Exclusion Criteria: * AML secondary to chronic leukemia and myeloproliferative neoplasms (MPNs) * With other underlying malignancies * Severe and uncontrolled infection * Intolerant to the chemotherapy
References
Publications (0)
Data not yet available